Screening for Biological Response Modifiers: Methods and Rationale / Najlacnejšie knihy
Screening for Biological Response Modifiers: Methods and Rationale

Code: 01401284

Screening for Biological Response Modifiers: Methods and Rationale

by James E. Talmadge, Isaiah J. Fidler, Robert K. Oldham

The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observat ... more

102.69

RRP: 111.29 €

You save 8.60 €


In stock at our supplier
Shipping in 10 - 13 days
Add to wishlist

You might also like

Give this book as a present today
  1. Order book and choose Gift Order.
  2. We will send you book gift voucher at once. You can give it out to anyone.
  3. Book will be send to donee, nothing more to care about.

Book gift voucher sampleRead more

More about Screening for Biological Response Modifiers: Methods and Rationale

You get 249 loyalty points

Book synopsis

The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for "screening" drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).

Book details

Book category Books in English Medicine Clinical & internal medicine Diseases & disorders

102.69

Trending among others



Collection points Bratislava a 12730 dalších

Copyright ©2008-26 najlacnejsie-knihy.sk All rights reservedPrivacyCookies


Account: Log in
Všetky knihy sveta na jednom mieste. Navyše za skvelé ceny.

Shopping cart ( Empty )

For free shipping
shop for 59,99 € and more

You are here: